Mo Huang

1.9k total citations · 1 hit paper
40 papers, 1.1k citations indexed

About

Mo Huang is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mo Huang has authored 40 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Cancer Research. Recurrent topics in Mo Huang's work include Single-cell and spatial transcriptomics (5 papers), CRISPR and Genetic Engineering (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Mo Huang is often cited by papers focused on Single-cell and spatial transcriptomics (5 papers), CRISPR and Genetic Engineering (4 papers) and Cancer Immunotherapy and Biomarkers (4 papers). Mo Huang collaborates with scholars based in United States, Singapore and China. Mo Huang's co-authors include Nancy R. Zhang, Jingshu Wang, Mingyao Li, Sydney M. Shaffer, Eduardo A. Torre, Arjun Raj, Hannah Dueck, John I. Murray, Roberto Bonasio and Mo‐Huang Li and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Blood.

In The Last Decade

Mo Huang

37 papers receiving 1.1k citations

Hit Papers

SAVER: gene expression recovery for single-cell RNA seque... 2018 2026 2020 2023 2018 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. SAVER: gene expression recovery for single-cell RNA sequencing
    2018 458 citations Mo Huang, Jingshu Wang et al. Nature Methods profile →

Peers

Mo Huang
Kok Siong Ang Singapore
Lassi Paavolainen Finland
Chenghua Yang China
Billy T. Lau United States
Qingyuan Zhu United States
Cesar A. Vargas-García United States
David Basiji United States
Daniel Schraivogel Germany
Kok Siong Ang Singapore
Mo Huang
Citations per year, relative to Mo Huang Mo Huang (= 1×) peers Kok Siong Ang

Countries citing papers authored by Mo Huang

Since Specialization
Citations

This map shows the geographic impact of Mo Huang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mo Huang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mo Huang more than expected).

Fields of papers citing papers by Mo Huang

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mo Huang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mo Huang. The network helps show where Mo Huang may publish in the future.

Co-authorship network of co-authors of Mo Huang

This figure shows the co-authorship network connecting the top 25 collaborators of Mo Huang. A scholar is included among the top collaborators of Mo Huang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mo Huang. Mo Huang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Luke, Jason J., Randy F. Sweis, J. Randolph Hecht, et al.. (2025). Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas. Clinical Cancer Research. 31(7). 1233–1242. 10 indexed citations
2.
Eng, Whitney, Ionela Iacobas, Jonathan A. Perkins, et al.. (2025). Safety findings from the phase 1/2 MOSAIC study of miransertib for patients with PIK3CA-related overgrowth spectrum or Proteus syndrome. Orphanet Journal of Rare Diseases. 20(1). 375–375.
3.
Huang, Mo, Cong Chen, & Linda Sun. (2023). Statistical Interpretation and Comparison of Waterfall Plots. JCO Clinical Cancer Informatics. 7(7). e2300132–e2300132.
4.
Pant, Shubham, Erika Hamilton, Susanna V. Ulahannan, et al.. (2023). Phase 1b study of pan‐AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN‐mutated advanced solid tumors. Cancer. 129(12). 1919–1929. 4 indexed citations
5.
Gregory, Gareth P., Shaji Kumar, Ding Wang, et al.. (2021). Pembrolizumab plus dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Advances. 6(4). 1232–1242. 24 indexed citations
6.
7.
Ahn, M-J., Dariusz M. Kowalski, Byoung Chul Cho, et al.. (2021). 116TiP KEYNOTE-B98: Phase Ib/II study of pembrolizumab plus investigational agents as second-line treatment for anti–PD-1/PD-L1-refractory extensive-stage small cell lung cancer (ES-SCLC). Annals of Oncology. 32. S1425–S1426. 1 indexed citations
8.
Wang, Jingshu, Mo Huang, Eduardo A. Torre, et al.. (2018). Gene expression distribution deconvolution in single-cell RNA sequencing. Proceedings of the National Academy of Sciences. 115(28). E6437–E6446. 63 indexed citations
9.
Jin, Tengchuan, Mo Huang, Jiansheng Jiang, Patrick Smith, & Tsan Sam Xiao. (2018). Crystal structure of human NLRP12 PYD domain and implication in homotypic interaction. PLoS ONE. 13(1). e0190547–e0190547. 9 indexed citations
10.
Huang, Mo, Jingshu Wang, Eduardo A. Torre, et al.. (2018). SAVER: gene expression recovery for single-cell RNA sequencing. Nature Methods. 15(7). 539–542. 458 indexed citations breakdown →
11.
Jin, Tengchuan, W. Chuenchor, Jiansheng Jiang, et al.. (2017). Design of an expression system to enhance MBP-mediated crystallization. Scientific Reports. 7(1). 40991–40991. 42 indexed citations
12.
Huang, Mo, et al.. (2016). Cost-Effectiveness of Pembrolizumab vs. Docetaxel for Treatment of Previously Treated PD-l1 Positive Advanced NSCLC Patients. Value in Health. 19(7). A737–A737. 3 indexed citations
13.
Huang, Mo, Yudong Lu, Min Jiang, et al.. (2015). Autoantibodies to chromogranin A are potential diagnostic biomarkers for non-small cell lung cancer. Tumor Biology. 36(12). 9979–9985. 11 indexed citations
14.
Jin, Tengchuan, Mo Huang, Patrick Smith, Jiansheng Jiang, & Tsan Sam Xiao. (2013). The structure of the CARD8 caspase-recruitment domain suggests its association with the FIIND domain and procaspases through adjacent surfaces. Acta Crystallographica Section F Structural Biology and Crystallization Communications. 69(5). 482–487. 13 indexed citations
15.
Hu, Min, Mo Huang, Wai Chye Cheong, et al.. (2012). Microsieve lab-chip device for rapid enumeration and fluorescence in situ hybridization of circulating tumor cells. Lab on a Chip. 12(21). 4388–4388. 148 indexed citations
16.
Huang, Mo, Jianan He, Jianhong Gan, & Hongwei Ma. (2010). Solidified liquid layer model makes quartz crystal microbalance a convenient molecular ruler. Colloids and Surfaces B Biointerfaces. 85(1). 92–96. 13 indexed citations
17.
Cheong, Wai Chye, et al.. (2010). New insights into the de novo gene synthesis using the automatic kinetics switch approach. Analytical Biochemistry. 406(1). 51–60. 7 indexed citations
18.
Huang, Mo, et al.. (2009). Preliminary results on GPU Acceleration of the PIC Simulation Code OSIRIS Using CUDA. Bulletin of the American Physical Society. 51. 1 indexed citations
19.
Huang, Mo, et al.. (2009). Experimental analysis of gene assembly with TopDown one-step real-time gene synthesis. Nucleic Acids Research. 37(7). e51–e51. 12 indexed citations
20.
Huang, Mo, et al.. (2008). Integrated two-step gene synthesis in a microfluidic device. Lab on a Chip. 9(2). 276–285. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kok Siong Ang Breakdown of academic impact, for papers by Lassi Paavolainen Breakdown of academic impact, for papers by Chenghua Yang Breakdown of academic impact, for papers by Billy T. Lau Breakdown of academic impact, for papers by Qingyuan Zhu Breakdown of academic impact, for papers by Cesar A. Vargas-García Breakdown of academic impact, for papers by David Basiji Breakdown of academic impact, for papers by Daniel Schraivogel
Rankless by CCL
2026